immunosuppressant
PharmacologyIn Vitro and In Vivo Assessment of FK506 Analogs as Novel Antifungal Drug CandidatesFK506 (tacrolimus) is an FDA-approved immunosuppressant indicated for the prevention of allograft rejections in patients undergoing organ transplants. In mammals, FK506 inhibits the calcineurin-nuclear factor of activated T cells (NFAT) pathway to prevent T-cell proliferation by forming a ternary complex with its binding protein, FKBP12, and calcineurin.